Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating

Inclusion Criteria: * Clinical diagnosis of a Depressive disorder (Diagnostic and Statistical Manual of Mental Disorders - IV-TR) * Presence of excessive sweating by self-report * The excessive sweating started after initiation of an antidepressant and, if treatment with the antidepressant was interrupted, did not persist for more than 4 weeks during that interruption * Treatment with the antidepressant is deemed to be clinically necessary due to substantial benefit from this antidepressant, and failure to respond to or tolerate an alternative * Excessive sweating has persisted for at least 4 weeks prior to baseline assessment * The excessive sweating is rated by the patient as at least moderately bothersome. * Episodes of excessive sweating occur at least twice a week for last 4 weeks Exclusion Criteria: * Presence of another known disease that could potentially cause excessive sweating * Failure to respond to antiadrenergic (reducing activity of the sympathetic nervous system) treatment in the past * Blood pressure less than 110 mm Hg systolic at the screening or baseline visits * Orthostatic hypotension by history or on assessment at the screening or baseline visits (defined as a decrease of 10 mm Hg or greater after standing for 2 minutes). * Current antihypertensive treatment * History of significant cardiac disease, including coronary artery disease * Current use of phosphodiesterase type 5 inhibitors: sildenafil (Viagra™), tadalafil (CialisTM), or vardenafil (LevitraTM) * History of priapism (persistent and painful erection)